Johnson & Johnson raises 2026 reported sales guidance to $101.1 bln at midpoint.
Company increases 2026 adjusted EPS guidance by $0.13 to $11.68 at midpoint.
Johnson & Johnson expects continued momentum from innovation and pipeline approvals.
Overview
U.S. healthcare conglomerate's Q2 sales rose 6.6%, beating analyst expectations.
Adjusted EPS for Q2 increased 4.7% to $2.90, beating analyst expectations.
Company raised 2026 sales and adjusted EPS guidance after strong operational performance.
Result drivers
Oncology and neuroscience growth - Co said operational sales growth was driven by oncology products such as DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and neuroscience drugs SPRAVATO and CAPLYTA.
Immunology declines offset gains - Co said growth was partially offset by lower sales of STELARA and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology.
MedTech expansion - Co said 3.6% operational growth in MedTech sales was driven by wound closure and biosurgery products in Surgery, electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Johnson & Johnson is $264.00, about 4% above its July 14 closing price of $253.85.
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago.
JNJ•
